Genetic Validation Aminoacyl-tRNA Synthetases Drug Targets Trypanosoma brucei
Savitha Kalidas Igor Cestari,b Severine Monnerat,b Qiong Li Sandesh Regmi Nicholas Hasle,b Mehdi Labaied,b Marilyn Parsons,b
Kenneth Stuart,b Margaret  Phillipsa
Department Pharmacology, University Texas Southwestern Medical Center, Dallas, Texas, USAa; Seattle Biomedical Research Institute, Seattle, Washington, USAb

Human African trypanosomiasis (HAT) important public health threat sub-Saharan Africa. Current drugs unsatis-
factory, new drugs sought. validated enzyme targets available support drug discovery efforts, goal obtain essentiality data genes proven utility drug targets. Aminoacyl-tRNA synthetases (aaRSs) known
drug targets bacterial fungal pathogens required protein synthesis. survey essentiality Trypanosoma brucei aaRSs RNA interference (RNAi) gene expression knockdown, covering enzyme major aaRS
class: valyl-tRNA synthetase (ValRS) (class Ia), tryptophanyl-tRNA synthetase (TrpRS-1) (class Ib), arginyl-tRNA synthetase
(ArgRS) (class Ic), glutamyl-tRNA synthetase (GluRS) (class 1c), threonyl-tRNA synthetase (ThrRS) (class IIa), asparaginyl-
tRNA synthetase (AsnRS) (class IIb), phenylalanyl-tRNA synthetase (â?£ â?¤) (PheRS) (class IIc). Knockdown mRNA
encoding enzymes T. brucei mammalian stage parasites showed essential parasite growth survival vitro. reduced expression resulted growth, morphological, cell cycle, DNA content abnormalities. ThrRS char-
acterized greater  showing purified recombinant enzyme displayed ThrRS activity protein localized cytosol mitochondrion. Borrelidin, known inhibitor ThrRS, inhibitor T. brucei ThrRS showed
antitrypanosomal activity. data aaRSs essential T. brucei survival likely excellent targets drug discovery efforts.



H     uman African trypanosomiasis (HAT), known African
      sleeping sickness, caused Trypanosoma brucei, proto-
zoan parasite transmitted tsetse flies genus Glossina (1).
                                                                                      distinguished different structural folds site                                                                                       esterification (class enzymes esterify 2=-hydroxyl aden-
                                                                                      osine ribose class II enzymes esterify 3=-hydroxyl HAT endemic 36 countries threatens 60 million                     ribose). Inhibitors aaRSs antibacterial anti-
people sub-Saharan Africa. drugs available treat                    fungal activity reported, mupirocin (used HAT, use complicated limited efficacy depends                    topical antibiotic) currently aaRS inhibitor clinical subspecies development stage parasite                      use, various stages discovery develop-
(2, 3). Treatment late-stage disease particularly problematic,                  ment (11â€“13)  Table 1). Recent examples identification recent introduction nifurtimox-eflornithine                          aaRS inhibitors targeting parasitic protozoa 
combination therapy (NECT) improved treatment outcomes                            scribed, including discovery cladosporin targets Plasmo-
(4), effective drugs combat forms disease                    dium falciparum LysRS, providing potential lead malaria badly needed.                                                                   drug discovery (19). targeted aaRSs diverse, spanning
    Alliances academic industry partners emerged                       different amino acid specificities different enzyme goal exploiting molecular-target approach antipa-                  classes.  aaRSs appear broadly appealing targets rasitic drug discovery (5, 6). open-access resource (tdrtargets.org)               development new antimicrobial agents. developed improve prioritization potential drug targets                     Trypanosomatids encode complement class 1 major pathogens (7, 8). premise undertaking idea                   class 2 aaRSs; bioinformatics analysis Leishmania major (20) gene products exploited treatment hu-                  T. brucei (21) identified 25 24 genes encoding canonical
man disease likely represent druggable targets                 aaRS homologs, respectively, covering key amino acids. Addi- information available (9). Druggable targets                     tionally, encode multiple-aaRS (MARS) complex-asso- defined bind small drug-like molecules high                ciated proteins (MCPs). MCPs share sequence identity potency, resulting disease-modifying outcomes. reported                      aaRS noncatalytic domains aaRS editing domains computational approaches utilized availability inhibitors homologs gene drug-like properties inhibitors assign targets druggability score.                                                        Received 15 January 2014 Accepted 13 February 2014
    translation apparatus, including ribosomes, specific elon-                          Published ahead print 21 February 2014
gation initiation factors, aminoacyl-tRNA synthetases                               Address correspondence Margaret  Phillips,
(aaRSs), represents major pathways targeted com-                              margaret.phillips@UTSouthwestern.edu.
mercial antibiotics (10â€“14). aaRSs essential participants                        Supplemental material article http://dx.doi.org/10.1128 protein translation mechanism, catalyzing esterification                         /EC.00017-14.
specific amino acids corresponding tRNAs (15â€“18) (Fig.                            Copyright Â© 2014, American Society Microbiology. Rights Reserved.
1). classes aaRSs described,                           doi:10.1128/EC.00017-14
turn divided additional subclasses. classes 

504   ec.asm.org                                            Eukaryotic Cell   p. 504 â€“516                                                  April 2014 Volume 13 Number 4
                                                                                                                       T. brucei Aminoacyl tRNA Synthetases



                                                                             (GluRS) obtained particle counting, detects cell debris.
                                                                             growth data collected biological triplicate, exception
                                                                             PheRSâ?£ GluRS data, collected duplicate. FIG 1 Reactions catalyzed aaRR. AA, amino acid substrate; aaRS:AA-AMP,    determine 50  effective concentration (EC50) borrelidin, enzyme-bound aminoacyl-adenylate intermediate; AA-tRNA, amino acyl
                                                                             dose-response data fitted log(inhibitor) versus response â«º
tRNA.
                                                                             variable slope (4-parameter) equation using GraphPad Prism.
                                                                                 Generation cell lines containing inducible RNAi constructs. RNA
                                                                             interference (RNAi) cell lines generated using gateway vector aminoacylation activity (21). cytosolic translation            (TrypRNAiGate) following genes: AsnRS (Tb927.4.2310), PheRSâ?£ mitochondrial translation require aaRSs. Trypanosomatids,                subunit (Tb927.11.14120), PheRSâ?¤ subunit (Tb927.11.2360), ValRS
unlike eukaryotes, code tRNA molecules             (Tb927.6.4480). 400- 500-bp region gene selected using
mitochondrial genome; instead, mitochondria import                     RNAit software (41). PCR products generated using High Fidelity
tRNAs aaRSs cytosol (13, 22, 23). aaRSs           Platinum Taq DNA polymerase (Invitrogen) following forward T. brucei genome single copy serve dual roles          reverse primer pairs: AsnRS, 5=-(CGGGCTACATTCAAGTGGT cytosol mitochondria; TrpRS, LysRS, AspRS                 T)-3= 5=-(CAAAATTGCACACCGCATAC)-3=; PheRSâ?£ subunit,
                                                                             5=-(TTTTAAGTCGCTGGAAGCAGGT)-3= 5=-(GGGGGCCCACGT notable exceptions separate cytosolic mitochon-
                                                                             CTAACACTAA)-3=; PheRSâ?¤ subunit, 5=-(AATGGGTACTGCGATG
drial genes identified (24â€“26). T. brucei aaRS             AAGG)-3= 5=-(TGATGCACGAGTAGTCCGAG)-3=; ValRS
genes reported essential parasites          5=-(GGGTACGACAGGAAGGTTGA)-3= primer 5=-(AATGTCACC
insect stage (procyclic) mammalian stage (21, 25â€“30).             GGTCCTACTGC)-3=. Gel-purified PCR fragments incubated
eral groups reported identification MetRS, IleRS,           pCR8/GW/TOPO vector (supplied ready use) 5 min room LeuRS inhibitors antitrypanosome activity (30â€“35).                  temperature, transformed Top10 Escherichia coli, plated spec-
Crystal structures solved aaRSs             tinomycin (100 â?®g/ml)-containing LB plates described Gateway species (15), including structures HisRS (36)             pENTR vectors instruction manual (Invitrogen Life Technologies). Se-
TrpRS (37) T. brucei, aid understanding            quence-verified plasmids used LR recombination 
target enzymes HAT drug discovery. Finally, recently            action pTrypRNAiGate destination vector generate stem-loop
showed number aaRSs T. brucei associate                constructs, parasite transfections performed previ-
MARS complex (21).  despite extensive efforts,               ously described (38, 39). Inducible RNAi plasmids ArgRS
                                                                             (Tb927.11.1990), ThrRS (Tb927.5.1090), TrpRS-1 (Tb927.3.5580),
number T. brucei key aaRSs remain uncharacterized.
                                                                             GluRS (Tb927.6.4590) generated using pQuadra     aaRSs successful drug targets species,          (42). Briefly, â¬ƒ400-bp fragment gene selected using RNAit undertook comprehensive study identify essential aaRSs            software (41) amplified PCR, using following forward reverse
T. brucei goal demonstrating potential utility        primer pairs, containing added BstXI sites 5= end: ArgRS, 5=- new class targets antitrypanosome drug discovery. pres-            TACCAATGTGATGGGCTTGTGGACTTTTCTTCGC)-3= 5=-(ATAC
ent study focused genetic validation uncharacter-            CATAGAGTTGGCTTTGCGTCCAGTGCAGATA)-3=; ThrRS, 5=-(ATA
ized T. brucei aaRSs RNA interference (RNAi) gene knockdown               CCAATGTGATGGATGTTTATGACGTCCTCGGC)-3= 5=-(ATACCA infectious mammalian bloodstream-form (BSF) parasites.                TAGAGTTGGGTGCAGCCTTCTCGTAGGAC)-3=; TrpRS-1, 5=-(ATA
Genes selected high druggablity scores               CCAATGTGATGGCTGCTATACAGGCTGCACCA)-3= 5=-(ATACCA
compass examples major aaRS classes.                TAGAGTTGGCCAATTTCCGTTTCTCCTGA)-3=; GluRS, 5=- newly characterized genes essential mam-         ACCAATGTGATGGTTTACGGGCAAAGATATCCG)-3= 5=-(ATACC
                                                                             ATAGAGTTGGCAACAACACATCGGACCTTG)-3=. Ligation BstXI-
malian BSF parasites. partial correlation                                                                              digested PCR fragments pQuadra3 plasmids generated RNAi vectors,
extent RNAi knockdown effects cell growth, mor-
                                                                             containing inverted repeats PCR product separated spacer region.
phology, cell cycle, cellular DNA. heterologous expression             Transfection NotI-linearized constructs SM cell line (43) se- enzyme assay developed threonyl-tRNA                  lection transgenic cell lines (44) carried described previously.
synthetase (ThrRS) ready target future work drug               Quantitative real-time PCR analysis. Quantitative real-time PCR discovery program.                                                           performed using SYBR green Mastermix (Bio-Rad). Total RNA ex-
                                                                             tracted parasites using TRIzol reagent (Invitrogen) RNeasy
MATERIALS METHODS                                                        minikit (Qiagen), treated DNase (Worthington), reverse tran-
TriTrypDB accession numbers genes analyzed study. Putative       scribed using High Capacity cDNA reverse transcription kit (Applied
aaRS genes selected based annotation TriTrypDB,     Biosystems). approximately 100-bp fragment gene ampli-
following studied: ThrRS (T. brucei 927.5.1090 [Tb927.5.1090]),         fied using SYBR green Mastermix CFX96 real-time (Bio-
arginyl-tRNA synthetase (ArgRS) (Tb927.11.1990), asparaginyl-tRNA            Rad). Reaction conditions maintained according manufacturerâ€™s
synthetase (AsnRS) (Tb927.4.2310), phenylalanyl-tRNA synthetase alpha        instructions follows: 95Â°C 1 min 40 cycles 95Â°C 3 s
(PheRSâ?£) subunit (Tb927.11.14120), PheRSâ?¤ subunit (Tb927.11.2360),           60Â°C 30 s, followed continuous melting curve (55Â°C 95Â°C
tryptophanyl-tRNA synthetase (TrpRS-1) (Tb927.3.5580), valyl-tRNA            0.5Â°C increments). Data normalized constitutively
synthetase (ValRS) (Tb927.6.4480), glutamyl-tRNA synthetase              expressed control mRNA, telomerase reverse transcriptase (TERT),
(GluRS) (Tb927.6.4590).                                                      validated control quantitative PCR (qPCR) T.
    Growth T. brucei BSF vitro cultures. BSF 427 single-marker         brucei (45). Gene expression levels quantified comparative
(SM) cells cultured HMI-9 media supplemented 10  fetal          threshold cycle (âŒ¬âŒ¬CT) method (46) TERT internal standard
bovine serum described previously (38â€“40). Cells maintained       normalization. Oligonucleotides follows: forward primer 5=-
exponential growth  105 106 cells/ml), RNAi           (GAGCGTGTGACTTCCGAAGG)-3= reverse primer 5=-(AGGAAC
duced cell density 2 â«» 105/ml addition tetracycline (Tet) (1   TGTCACGGAGTTTGC)-3= TERT, forward primer 5=-(AATGCGAA
â?®g/ml) media. Cell numbers monitored hemocytometer,           GGATTTGTCCAC)-3= reverse primer 5=-(TGCTCGGAGAGTTTC exception data collected glutamyl-tRNA synthetase      ACCTT)-3= AsnRS, forward primer 5=-(TTATGGAGATGGGCTTCC


April 2014 Volume 13 Number 4                                                                                                               ec.asm.org 505
                                                                                                                                                                                                                                                           Eukaryotic Cell
                 TABLE 1 Classification druggability T. brucei aaRSsa
                                                                                                                                                                                                                            RNA          Loss fitness
                                                                                               BSF                                                                                            BSF RNAi growth       knockdown      BSF RNAi
                 Product     Gene ID             Class   Localization    MARS complex         RNA reads     Druggability    Chemical validation                      Structure(s) available         defect                (24 h)         screen (3)
                 AlaRS       Tb927.6.700         IIc     C/M             Y                    589.1         0.2                                                                                     Severe (21)           78             Yes
                 ArgRS       Tb927.11.1990       Ic      C/M             Y (Homo sapiens)     302.2         0.6                                                                                     Severe                79             Yes
                 AsnRS       Tb927.4.2310        IIb     C/M             Y                    566.3         data                                                                                 Severe                60             Yes
                 AspRS-2     Tb927.10.1260       IIb     M                                    108.4         data         Microcin C (63)                                                                                                               AspRS-1     Tb927.6.1880        IIb     C                                    98.3          0.2             Microcin C (63)                          Y (Homo sapiens)                                                                     CysRS       Tb927.6.950         Ia      C/M             Y                    517.0         data                                                                                                                                       GlnRS       Tb927.9.5210        Ic      C/M                                  345.0         0.8             Glu-KPA (E. coli) (64)                   Y (Saccharomyces cerevisiae)                                        Yes
                 GluRS       Tb927.6.4590        Ic      C/M             Y                    465.1         0.3                                                      Y (Saccharomyces               Moderate                             Yes
                                                                                                                                                                        cerevisiae)
                 GlyRS       Tb927.11.9640       IIc     C/M             Y                    302.4         data                                                                                                                      Yes
                 HisRS       Tb927.6.2060        IIa     C(M?)                                100.0         0.6                                                      Y (T. brucei)                  Severe (36)           58             Yes
                 IleRS       Tb927.10.9190       Ia      C/M             Y                    1000.2        0.9             Reveromicin (S. aureus) (65);            Y (Homo sapiens)               Severe (21)           80             Yes
                                                                                                                               muporicin (S. enterica) (66);
                                                                                                                               NSC70422 (T. brucei) (21); PLD-
                                                                                                                               118 (icofungipen) (C. albicans)
                                                                                                                               (67); SB-203207 (Streptomyces)
                                                                                                                               (68, 69)
                 LeuRS       Tb927.11.3730       Ia      C/M                                  320.1         0.7             Granaticin (B. subtilis) (67);                                          Moderate (21)         64                              LysRS-1     Tb927.8.1600        IIb     C/M                                  400.2         data         Cladosporin (Plasmodium                  Y (Homo sapiens,               Severe (21)           73                                                                                                                                            falciparum) (19)                         Plasmodium falciparum)
                 LysRS-2     Tb927.6.1510        IIb     M                                    105.9         data                                                                                                                                       MetRS       Tb927.10.1500       Ia      C/M             Y                    326.4         0.7             Urea-based inhibitors (T. brucei) (33,   Y (T. brucei, Leishmania       Moderate (21)         77                                                                                                                                           35); REP8839 (S. aureus) (70)             major)
                 PheRS-â?£     Tb927.11.14120      IIc     C/M             Y (Saccharomyces     283.1         0.6             Ochratoxin B (hepatoma                                            Moderate              57                                                                                         cerevisiae)                                       tissue culture) (71);
                                                                                                                              ethanolamine-based inhibitors
                                                                                                                              (Staphylococcus aureus) (72)
                 PheRS-â?¤     Tb927.11.2360       IIc     C/M                                  248.2         data                                                                                 Severe                73             Yes
                 ProRS       Tb927.10.12890      IIa     C/M             Y                    859.4         0.8             Halofuginone (Plasmodium) (73)           Y (Homo sapiens)               Severe (21)           53             Yes
                 SerRS       Tb927.11.7170       IIa     C/M                                  308.5         data         SB-217452 (rat, S. aureus) (74)          Y (T. brucei, Homo sapiens)                                         Yes
                 ThrRS       Tb927.5.1090        IIa     C/M             Y (Saccharomyces     372.0         0.6             Borrelidin (fungi, bacteria) (53, 55,    Y (Saccharomyces               Severe                84                                                                                         cerevisiae)                                       56); T. brucei  work)                cerevisiae, Homo
                                                                                                                                                                        sapiens, Escherichia
                                                                                                                                                                        coli)
                 TrpRS-1     Tb927.3.5580        Ib      C               Y                    168.4         0.2             Chuangxinmycin (bacteria) (73);          Y (T. brucei), Plasmodium      serere                59                                                                                                                                           indolmycin (Streptomyces) (73)            falciparum
                 TrpRS-2     Tb927.8.2240        Ib      M                                    117.4         0.2                                                      Y (Plasmodium falciparum)      Severe (conditional                                                                                                                                                                                                                         null) (27)
                 TyrRS       Tb927.7.3620        Ib      C/M                                  200.0         0.6             3-Aryl-4-arylaminofuran-2(5H)-ones       Y (Leishmania major)                                                                                                                                                                              (bacteria) (75); SB-219383
                                                                                                                              (Micromonospora sp.) (76)
                 ValRS       Tb927.6.4480        Ia      C/M                                  402.0         0.9             S-Adenosylhomocysteine (77)                                             Moderate              63                              MCP1        Tb927.7.2400                                                     221.2         data                                                                                 Unknown
                 MCP2        Tb927.8.5330                C                                    80.6                                                                                                  Moderate (21)         100
                                                                                                                                                                                                      (conditional
                                                                                                                                                                                                      null)
                 MCP3        Tb927.10.1250                                                    68.7                                                                                                  Unknown
                                    Gene names (http://tritrypdb.org/tritrypdb/) druggability scores (tdrtargets.org) taken indicated web sites. Enzymes evaluated study shown bold type. Loss fitness data RNAi screen 
                 formed Alsford et al. (3) summarized comparison. BSF RNA reads scaled read counts (median normalized; median 100) taken reference 78. MARS complex-associated proteins (MCP) 1 1, 2, 3 shown,




                                                                                                                                                                                                                                                           ec.asm.org
                 aaRS activity. C, cytoplasm; M, mitochondrion; C/M, cytoplasm mitochondrion; Glu-KPA, glutamyl-beta-ketophosphonate-adenosine; Y, yes. Numbers parentheses refer publications cited.
Kalidas et al.



                 ID, identification number.




                                                                                                                                                                                                                                                           506
                                                                                                                        T. brucei Aminoacyl tRNA Synthetases



AG)-3= reverse primer 5=-(GCGGGTTTTGAAATGAAGAA)-3=                         Aminoacylation spectrophotometric assays. Amino acylation assays
PheRSâ?£ subunit, forward primer 5=-(GGAGGACCAATTCGAAGA                          performed previously described (50). Briefly, T. brucei tRNAThr
CA)-3= reverse primer 5=-(AGAAAGCTCCTCTCCCTTGG)-3=                     synthesized vitro transcription PCR product template
PheRSâ?¤ subunit, forward primer 5=-(AAGAAGTATCACGGTAAGC)-3=                     contained T7 promoter followed tRNAThr sequence reverse primer 5=-(TCACATCAACCAGAACAG)-3= ValRS,                   (Tb927.8.2858) CCA sequence. tRNAThr template pro-
ward primer 5=-(CGCTATGGGTCTTGTCAAGCT)-3= reverse                          duced PCR using primers overlap tRNAThr sequence: forward
primer 5=-(CAGTGCCGGGCTTGTCTTT)-3= ArgRS, forward                          [5=-(TAATACGACTCACTATAGGGGCCTCGTAGCACAGTGGC)-3=], B
primer 5=-(CCCGCGGCAAGTTATTGT)-3= reverse primer 5=-(TG                    reverse [5=-(TGGAGGCCCCGCCGAG)-3=], C forward [5=-(GGCCTCGTA
TCGCGCACCGTTTGT)-3= ThrRS, forward primer 5=-(ACGAG                    GCACAGTGGCAGTGCACTGGTCTTGTAAACC)-3=], D reverse [5=-
TCCGGTCAACCTTTTT)-3= reverse primer 5=-(TCAAATGACCCA                       (AGGCCCCGCCGAGAATTGAACTCGGGACCCCTGGTTTACAAGAC
TATGCATGGA)-3= TrpRS-1.                                                    CAGTGCAC)-3=]. standard reaction ingredients, unless     Cell morphology analysis. Log-phase cells collected centri-        stated, aminoacylation buffer (30 mM HEPES buffer [pH 7.4], 140 mM
fuging 3,000 rpm 10 min 15-ml tube. Cells resuspended      NaCl, 30 mM KCl, 40 mM MgCl2), 1 mM dithiothreitol (DTT), 200 â?®M
freshly 4  paraformaldehyde (PFA), fixed room temperature          ATP, 2 U/ml inorganic pyrophosphatase (Sigma-Aldrich), 10 mM L-Thr
45 min, washed phosphate-buffered saline (PBS; pH 7.4), resus-        (Sigma-Aldrich), 8 â?®M T. brucei tRNAThr, 0.4 â?®M recombinant
pended 50 100 â?®l PBS. Cells (20 â?®l) placed poly-L-lysine-      ThrRS. aminoacylation reactions (55 â?®l total volume  
coated slide, spread, dried 1 h. nuclear (N) kinetoplast (K)   formed clear, flat  96 plates (Costar 96 standard mi-
DNA, cells applied coverslips Vectashield mounting         croplates), reaction mixtures incubated 30 min 37Â°C.
dium containing DAPI (4=,6-diamidino-2-phenylindole; hard set)             Liberated inorganic phosphate detected addition 100 â?®l mal-
analyzed fluorescence confocal microscopy (Leica TCS SP5) mag-         achite green (Echelon Biosciences) incubated 30 min room
nification â«»63 excitation wavelength 350 nm bright-        temperature. Absorbance measured 620 nm using SpectraMax
field differential interference contrast (DIC). uninduced Tet-        M2 microplate reader (Molecular Devices). Reactions enzyme induced cultures examined multiple time intervals.                 L-Thr performed background controls, data percentage morphological anomalies (number nuclei, kinetoplasts,         reactions L-Thr subtracted measurements. phenotypic forms) determined counting 150 cells.                    time course experiments, aliquots 10 â?®l withdrawn 80-â?®l
    Flow cytometric analysis. cell cycle analysis, BSF T. brucei       reaction mixture different time points (0, 2.5, 5, 10, 20, 30, 60 min)
inoculated 105 parasites/ml cultures harvested 0, 2,    mixed 10 mM EDTA ice stop reaction. ThrRS
3 days plating. Cells washed PBS (pH 7.4) fixed 70          inhibition borrelidin, reaction mixture containing ThrRS (0.4 â?®M)
ethanol resuspended PBS containing 10 â?®g mlâ«º1 RNase 10            mixed 5 â?®l borrelidin 10 10,000 nM 50-â?®l volume
â?®g mlâ«º1 propidium iodide (PI; Sigma). incubation 30 min           incubated 30 min 37Â°C. Reactions stopped described
                                                                                data shown replicates means â«¾ standard
37Â°C, PI-stained cells analyzed flow cytometry described pre-
                                                                               errors. determine 50  inhibitory concentration (IC50) borre-
viously (47, 48). Histograms analyzed populations 2C, 4C,
                                                                               lidin, dose-response data fitted log(inhibitor) versus  â¬Ž4C measurement relative DNA content.
                                                                               sponse â«º variable slope (4-parameter) equation using GraphPad Prism
    Immunofluorescence localization assay. gene encoding ThrRS
                                                                               slope restrained 1.0.
(Tb927.5.1090) amplified PCR genomic DNA T. brucei
strain Lister 427 using specific primers forward 5=-(CCCAAGCTTATGG
CCACGGCTGTTG)-3= reverse 5=-(CCCAGATCTGAAGGACGGA                           RESULTS
TCATATTTATCGG)-3= cloned HindIII BamHI sites                   Gene selection. Enzymes selected analysis essentiality
pLEW100 vector 3V5 tag C terminus. Plasmids digested        T. brucei based criteria:  interested genes NotI transfected T. brucei SM 427 BSF cells, resistant       high druggability scores; second, sought study repre-
clones selected 5 â?®g/ml phleomycin (49). Expression        sentative major aaRS classes subclasses (Ta-
3V5-tagged protein induced 0.5 â?®g/ml Tet. Cells growing            ble 1). selected genes, ThrRS, ArgRS, AsnRS, ValRS, mid-log phase fixed 4  paraformaldehydeâ€“PBS (pH 7.4), ad-            GluRS single-copy genes dual cytosolic mito-
hered poly-L-lysine-treated 12-mm-diameter cover glass (Fisher),        chondrial localizations based reported proteomic analysis
permeabilized 0.2  Triton X-100 â€“PBS. Coverslips blocked
                                                                               (21, 51). contrast, TrpRSs encoded T. brucei 3  bovine serum albumin (BSA)â€“PBS labeled monoclonal
antibodies 3V5 tag (anti-V5-fluorescein isothiocyanate [FITC;
                                                                               genome, cytosolic enzyme analyzed study. Sigma] conjugated) diluted 1:500 PBSâ€“3  BSA. Mitochon-            subunits PheRS studied; alpha subunit consists drial staining performed treating cells 0.01 â?®g/ml Mito-           catalytic core, beta subunit consists DNA ATP
Tracker (Molecular Probes/Invitrogen) 30 min 37Â°C 5  C02             binding sites. Druggability scores obtained tdrtarget- fixation. DNA stained described  Cells analyzed       s.org showed good predicted druggability ThrRS, PheRS, Deltavision fluorescence microscope (Olympus IX70).                     ArgRS, ValRS (â¬Ž0.6 based range 0 1, 1
    Cloning, expression, purification recombinant protein.          representing druggable targets [7, 8]), suggesting  gene ThrRS (Tb927.5.1090) amplified PCR using specific prim-        essential, strong candidates drug discovery pro-
ers forward 5=-(CCCGAATTCATGGCCACGGCTGTTGTT)-3=                         grams. Druggability data available AsnRS, TrpRS-1
verse 5=-(CCCGTCGACGAAGGACGGATCATATTT)-3= genomic                         GluRS score 0.6 threshold good druggability.
DNA T. brucei strain SM 427 cloned pET28aâ«¹ vector (Nova-              Aminoacyl tRNA synthetases essential BSF T. brucei
gen) using EcoRI XhoI restriction sites C-terminal 6â« tag.
                                                                               growth. test selected aaRSs essentiality T. brucei BSF constructs transformed E. coli Rosetta 2(DE3) strain pLysS
(Novagen), protein expression induced 0.1 mM IPTG (iso-
                                                                               parasites, established stable transgenic cell lines allow
propyl-â?¤-D-thiogalactopyranoside). E. coli grown LB media           Tet-inducible RNAi-mediated ablation enzyme expression.
harvested, lysate prepared Bugbuster reagent (Novagen).         Stem-loop RNAi constructs generated using Gate-
Proteins purified using Niâ«¹2 magnetic beads (Millipore), dialyzed         way pQuadra cloning enzymes ThrRS, AsnRS, 50 mM Tris (pH 7.4)â€“140 mM NaCl, kept 4Â°C  0.05            PheRSâ?£, PheRSâ?¤ belonging class II tRNA synthetases sodium azide) use.                                                       ArgRS, TrpRS-1, ValRS, GluRS belonging class aaRSs


April 2014 Volume 13 Number 4                                                                                                               ec.asm.org 507
Kalidas et al.




FIG 2 Effect RNAi-induced knockdown ThrRS BSF T. brucei. Independent RNAi cell lines generated BSF cells ThrRS analyzed growth cell cycle progression following RNAi induction.   Growth curves clonal lines Tet (data represent means, error bars
represent ranges). Cell numbers monitored hemocytometer, cell number calculated product cell density total dilution. (B)
Real-time qPCR analysis uninduced cells cells treated Tet 24 h 48 h relative TERT normalization standard. Analyses run triplicate, error bars represent root mean square deviation (RMSD). (C) Genome analysis microscopy: distributions nuclei (N) kinetoplasts
(K). Cells grown Tet 48 h, stained DAPI, examined fluorescence microscopy. total 150 cells counted condition.
(D E) Flow analysis cells minus (D) plus (E) Tet 48 h stained propidium iodide (PI). PI fluorescence (FL3-Area) plotted versus cell count. tallest peak panel D represents G0/G1 (48 ), span peaks represents S phase (4.59 ), second tallest peak represents G0/M (27.6 ).
(F) Confocal imaging representative cells Tet induction (48 h).



(Table 1). Figures 2, 3, 4, 5, 6, 7 characterization               trol wild-type SM cells stained PI DNA content aaRS knockdowns, Fig. 8 depicts character-                   analyzed flow cytometry. Cell morphology numbers istics parental line comparative purposes. 8             nuclei (N) kinetoplasts (K) additionally analyzed targeted genes, induction RNAi led significant growth defects                confocal microscopy following staining DAPI. Cells 2 3 days, showing 8 genes essential parasite            scored â€œnormalâ€? contained 1K1N 2K1N/2K2N
viability (Fig. 2A, panels Fig. 7, Table 2).                   â€œabnormalâ€? contained different genome compo-
growth defects correlated decreased mRNA levels ranging                       sition. majority (90  94 ) control populations 55  85  determined RT-PCR analysis using TERT                        normal phenotype, contained 1K1N, lesser control (Fig. 2B 7B Table 2) (RT-PCR analysis                     fraction dividing cells (2K1N 2K2N) observed (Fig. 8A GluRS cell knockdown line). Knockdown                     B). Based flow cytometry, 53  cells G0/G1
genes (ThrRS, AsnRS, PheRSâ?¤, ArgRS) led rapid cell death,                   phase, 4  S phase, 26  G2/M phase. evidence live cells detected past day 6. Knock-                     Dramatic morphological effects cell cycle changes remaining genes (PheRSâ?£, TrpRS-1, ValRS,                           observed ThrRS, ArgRS, AsnRS RNAi cell lines  GluRS) stopped growth did completely lyse cells                   lesser extent, PheRSâ?¤, morphological abnormalities level mRNA knockdown similar level seen                   observed early 16 h Tet induction (Fig. 2 5 genes showed robust cell death effect.                   Table 2). Flow cytometry suggested knockdown ThrRS led
note,  changes protein levels necessarily track                 accumulation cells low DNA content (Fig. 2D E). mRNA levels, protein levels measured,                  corresponded appearance 0N1K cells (4 ) remains possible protein levels decreased significantly               1N0K cells (3 ) (quantitated confocal microscopy) (Fig. 2C). cell lines showed robust effects.                             increase number 2N2K cells suggestive
    Morphology flow cytometric analysis T. brucei BSF                       block cytokinesis (Fig. 2C). Phenotypically, large percent-
cells aaRS knockdown. explore consequences gene                    age Tet-induced ThrRS RNAi cells rounded, detached
knockdown observed growth arrest, RNAi cell                         flagella, lacked motility (Fig. 2F). Knockdown ArgRS led lines Tet induced uninduced control cells                     rapid cell death increase number rounded cells


508   ec.asm.org                                                                                                                                     Eukaryotic Cell
                                                                                                                         T. brucei Aminoacyl tRNA Synthetases




FIG 3 Effect RNAi-induced knockdown ArgRS BSF T. brucei.   Growth curves. Cell numbers monitored hemocytometer. (B) Real-time qPCR
analysis. (C) Genome analysis microscopy. (D E) Fluorescence-activated cell sorter (FACS) analysis. (F) Confocal imaging. Details described Fig. 2.

 detached flagella (Fig. 3F), significant change DNA              creased populations 0N1K  20 ), 1N0K, 1N2K cells
content seen (Fig. 3D E). Knockdown AsnRS led                     (Fig. 4C E) suggestive block entering S phase. signifi-
increases abnormal complements nuclei kinetoplasts.                   percentage Tet-induced AsnRS RNAi cells confocal microscopy flow cytometry identified                       spherical round detached flagella flagella




FIG 4 Effect RNAi-induced knockdown AsnRS BSF T. brucei.   Growth curves. Cell numbers monitored hemocytometer. (B) Real-time qPCR
analysis. (C) Genome analysis microscopy. (D E) Flow analysis. (F) Confocal imaging. Details described Fig. 2.



April 2014 Volume 13 Number 4                                                                                                                ec.asm.org 509
Kalidas et al.




FIG 5 Effect RNAi-induced knockdown PheRS BSF T. brucei.  panels) Knockdown PheRSâ?£.   Growth curves. Cell numbers monitored hemocytometer. (B) Real-time qPCR analysis. (C) Genome analysis microscopy. (D E) Flow analysis. (F) Confocal imaging.  panels)
Knockdown PheRSâ?¤.   Growth curves. Cell numbers monitored hemocytometer. (B) Real-time qPCR analysis. (C) Genome analysis micros-
copy. (D E) Flow analysis. (F) Confocal imaging. Details described Fig. 2.



(Fig. 4F [arrow arrowhead]). knockdown PheRSâ?¤,               8C DNA content suggesting block cytokinesis (Fig. 5D DNA content normally distributed (Fig. 5C E,            E, panel), cell morphology looked fairly normal
panel) cells somewhat enlarged (Fig. 5F, panel).          (Fig. 5F, panel). Knockdown TrpRS-1 ValRS did    Milder notable effects cell cycle cell morphology       alter cell morphology (data shown), knockdown observed PheRSâ?£ knockdown (Fig. 5). Knockdown                 genes reduced rate cell growth, remaining cells PheRSâ?£ led strong increase populations cells, 4C          normal distribution DNA content (Fig. 6 7).  RNAi


510   ec.asm.org                                                                                                                     Eukaryotic Cell
                                                                                                                  T. brucei Aminoacyl tRNA Synthetases



                                                                            84 ) showing greater growth defects, exception                                                                             AsnRS cell lines showed decrease mRNA 60 ,
                                                                            sufficient lead cell lysis (Table 2).
                                                                                ThrRS enzymatic activity. Based strong cell death phe-
                                                                            notype observed ThrRS knockdown, decided character-
                                                                            ize protein greater  Recombinant ThrRS ex-
                                                                            pressed purified E. coli, used coupled-enzyme
                                                                            assay evaluate enzymatic activity following genera-
                                                                            tion pyrophosphate conversion inorganic phosphate,
                                                                            detected malachite green (50). ThrRS acylated
                                                                            tRNAThr time- enzyme concentration-dependent man-
                                                                            ner, demonstrating T. brucei ThrRS gene encodes func-
                                                                            tional enzyme (Fig. 9A B). assay remained linear 30
                                                                            min, taken representing steady-state phase                                                                             reaction, time point used subsequent studies.
                                                                            Enzyme concentrations 0.25 â?®M led loss linear
                                                                            dependence enzyme activity;  0.25 â?®M enzyme used
                                                                            subsequent studies. specific activity enzyme                                                                             conditions 1.4 minâ«º1, comparable published
                                                                            values yeast enzyme (kcat â«½ 2.8 minâ«º1 [52]).
FIG 6 Effect RNAi-induced knockdown TrpRS-1 BSF T. brucei.           provide chemical validation ThrRS drug target T.
Growth curves. Cell numbers monitored hemocytometer. (B) Real-      brucei, tested reported ThrRS inhibitor borrelidin time qPCR analysis. (C D) FACS analysis. Details described Fig. 2.                                                                     T. brucei ThrRS enzyme  activity, BSF T.
                                                                            brucei cells vitro. Borrelidin natural-product polyketide                                                                             reported broad-spectrum antimicrobial anticancer
knockdown aaRSs resulted morpholog-              activity (53â€“57). Borrelidin potent inhibitor T. brucei
ical cell division abnormalities growth inhibition               ThrRS (IC50 â«½ 0.066 â?®M), result consistent death. partial correlation degree            finding amino acids putative borrelidin binding RNAi knockdown morphological growth defects,                 pocket conserved T. brucei bacterial enzymes lines knockdown pronounced (73                 sensitive compound (53)  Fig. S1 supple-




FIG 7  panels) Effect RNAi-induced knockdown ValRS BSF T. brucei.   Growth curves. Cell numbers monitored hemocytometer. (B)
Real-time qPCR analysis. (C) Genome analysis microscopy.  panel) Effect RNAi-induced knockdown GluRS BSF T. brucei.   Growth
curves. Cells counted particle counting, detects cell debris. Details described Fig. 2.



April 2014 Volume 13 Number 4                                                                                                         ec.asm.org 511
Kalidas et al.



                                                                               tential family enzymes targets drug discovery T.
                                                                               brucei, assessed essentiality mammalian infective
                                                                               stage examples major aaRS class subclass (Table
                                                                               1) RNAi-based gene expression knockdown. RNAi resulted                                                                                growth inhibition  evident 
                                                                               tween days 1 4, depending cell line (Table 2). cell
                                                                               lines exhibited differences morphology DNA content
                                                                               (revealed flow cytometry profiles) RNAi induction. 
                                                                               aaRSs class essential normal growth mamma-
                                                                               lian stage T. brucei, data specifically provide genetic vali-
                                                                               dation seven key aaRSs potential drug targets parasite.
                                                                               Analysis recombinant T. brucei ThrRS demonstrated                                                                                enzyme catalytic efficiency similar enzymes                                                                                species inhibited borrelidin, natural-
                                                                               product inhibitor bacterial ThrRS. Borrelidin inhibited
                                                                               parasite growth, providing preliminary chemical validation                                                                                target.
                                                                                   date, including data reported  16 24 aaRSs
                                                                               shown essential BSF T. brucei (Table 1). Addi-
                                                                               tionally, aaRSs examined genome-wide RNAi
                                                                               fitness screen BSF cells (58). genes studied 
                                                                               AsnRS, PheRS â?¤, ArgRS, GluRS important fitness                                                                                screen, knockdown PheRSâ?£, ValRS, ThrRS,                                                                                TrpRS-1 did lead reduced fitness. level RNA knock-
                                                                               quantified screen, illustrating importance
                                                                               detailed analysis obtain conclusive results. genome-
                                                                               wide RNAi screen, highly essential genes,                                                                                aaRSs, leaky expression RNAi constructs absence
                                                                               Tet led selection parasites containing mutations                                                                                inducible T7 promoter. occurred, RNAi longer                                                                                expressed, leading normal growth cells false read                                                                                nonessentiality. study assessed essentiality FIG 8 Cell morphology FACS analysis wild-type SM T. brucei cells.     aaRSs localize mitochondrion, ap-
Genome analysis microscopy. (B) Confocal imaging. (C D) Flow anal-      peared essential BSF parasites.  RNAi showed ysis. Details described Fig. 2.                                     AspRS TrpRS-1 essential insect (procyclic)
                                                                               stage (23, 24, 25) analysis conditional null mitochon-
                                                                               drial TrpRS-2 BSF parasites showed essential (27). 
mental material). T. brucei BSF cell growth inhibited                 mitochondrial aaRSs mitochondrial protein synthesis
(EC50 â«½ 2.2 â?®M) (Fig. 9C), parasites 30-fold             essential mammalian stage parasites, im-
sensitive compound purified recombinant enzyme.                portant drug discovery, mitochondrial aaRSs difference relate poor uptake borrelidin                 divergent eukaryotic enzymes (21).
parasites, rule potential target effects                  aaRSs appear essential, equal
borrelidin parasites.                                                   potential drug targets implied differences responses
    Cell localization ThrRS. order determine localiza-            RNAi expression knockdown. included time course
tion ThrRS enzyme, prepared transgenic cell lines allow-
ing inducible expression ThrRS V5 tags C
terminus. Cells stained DAPI (nuclei) MitoTracker                TABLE 2 Description T. brucei BSF RNAi knockdown phenotypes
(mitochondria) mark compartments anti-V5                   analyzed studya
antibody. Tet-inducible diffuse staining tagged T. brucei                                             Time                                                                                                                growth
ThrRS observed, consistent cytosolic localization (Fig.                                      KD     defect     Cell morphology      DNA content FACS
10).  merged image showed evidence mito-                  Figure     aaRS        (24 h)   (h)         48 h)            microscopy
chondrial staining marked appearance yellow                 2          ThrRS       84       48         Round lyse    Increase 0N, 0K, cell edges position mitochondria. result                                                                                2K cells
                                                                               3          ArgRS       79       16         Round lyse    wild type
consistent T. brucei ThrRS gene encoding dual-purpose               4          AsnRS       60       16         Round lyse    Increase 0N, 0K, aaRS functions cytoplasm mitochondria                                                                                    2K cells
                                                                               5          PheRS-â?£     57       48         Normal               wild type good agreement prior mass spectrometry data (21).               5          PheRS-â?¤     73       24         Enlarge lyse     Increase 0N, 0K,                                                                                                                                                   2K cells
DISCUSSION                                                                     6          TrpRS-1     59       24         Normal lyse      wild type
                                                                               7          ValRS       63       48         Normal               wild type aaRSs validated antimicrobial drug targets high drug-             7          GluRS       ND       48         ND                   ND
gability scores (11â€“13). order systematically evaluate po-                                                                                              FACS, fluorescence-activated cell sorter analysis; KD, knockdown; ND, 



512   ec.asm.org                                                                                                                                       Eukaryotic Cell
                                                                                                                            T. brucei Aminoacyl tRNA Synthetases




FIG 9 Characterization ThrRS expression activity.   ThrRS activity assays recombinant protein purified E. coli. Data represent dependence PO4-2 formation versus time. (B) Dependence PO4-2 formation ThrRS concentration. moles PO4-2 formed mole tRNAThr acylated. (C) Dose response T. brucei BSF growth recombinant ThrRS activity versus concentration borrelidin, known ThrRS inhibitor. inhibition parasite growth, EC50 â«½ 2.2 â?®M (1.8 2.5); inhibition ThrRS activity, IC50 â«½ 0.066 â?®M (0.020 0.22), values parentheses represent 95  confidence interval.

 growth effects, effect cellular morphology, effect             zymes complex led severe growth pheno- DNA flow cytometric profile. data                    types knockdown  Knockdown genes studied  knockdown ThrRS, ArgRS, AsnRS,                      ArgRS, PheRSâ?¤, ThrRS, complex, PheRSâ?¤ led rapid cell death phenotypes                    caused severe growth effects, observed TrpRS-1 morphological cell cycle changes. different responses                 aaRSs complex (21). Finally, reported RNAi knockdown differences levels                    aaRSs alternative roles cell function, including remaining mRNAs proteins reflect differ-                  production dinucleotide polyphosphates, act sec-
ing cellular requirements enzyme, including relative cat-               ond messengers (59), amino acid sensing (60), transcriptional
alytic efficiency levels relationship substrate concentra-            regulation (61).  involvement enzyme cellular
tions enzyme Km. addition, cellular dependence                  process translation lead enhanced response enzyme affected functions cytosolic                 gene knockdown respect growth cell cycle changes mitochondrial compartments, integrated                      comparison genes involved translation.  MARS complex, enzyme                        likely factors, including degree alternative functions cellular processes addition pro-              mRNA loss, cellular requirement certain aaRS,
tein synthesis. degree mRNA reduction ex-                   cellular location, potential functions tent growth morphological abnormalities entirely                   aaRS, contribute phenotype considered correlate, gene knockdowns showed severe                   choosing particular aaRS drug target based essentiality
phenotypes (ThrRS, ArgRS, PheRSâ?¤, AsnRS), mRNA lev-                      data.
els 24 h reduced 60  84 ,                    Finally, essentiality consideration evaluating
moderate effects (PheRSâ?£, TrpRS-1, ValRS), mRNA levels                       enzyme good drug target. reduced 57  63  (Table 2).  data                  druggability target likelihood achieving selectiv- cases partial knockdown target required             ity versus human host need considered. genes
cause growth reductions, suggesting partial reduction               targeted current study, (ThrRS, ArgRS, PheRS, enzyme activity inhibitors affect parasite growth.               ValRS) high (â¬Ž0.6) druggability scores (Table 1), strengthens potential aaRSs successfully targeted              severe growth morphological changes observed drug discovery.                                                              knockdown ThrRS ArgRS, suggesting     assessing potential effects MARS complex es-                enzymes strong potential successfully targeted.
sentiality, knockdown enzyme MARS complex                    Furthermore, chemical validation strengthens case potentially lead destabilization complex structure              particular target, data showing borrelidin inhibited
changes abundance additional complex aaRSs.                    T. brucei ThrRS parasite growth provide preliminary chemical analysis did indication knockdown                    validation target, stage, direct proof 



FIG 10 Subcellular localization analysis T. brucei BSF expressing C-terminal V5-tagged ThrRS. Cells fixed 4  paraformaldehyde stained FITC-conjugated anti-V5 monoclonal antibodies. Mitochondria stained MitoTracker (MT), DNA stained DAPI. Differential interfer-
ence contrast (DIC) shown. Images merged indicated.



April 2014 Volume 13 Number 4                                                                                                                   ec.asm.org 513
Kalidas et al.



borrelidin growth effects consequence ThrRS inhibition        Science Education. C. awarded National Institutes Health
lacking. ThrRS localize cytoplasm           postdoctoral fellowship (5T32AI007509-12).
mitochondrion, possible inhibition cell growth consequence protein synthesis inhibition cellular            REFERENCES
compartments.                                                              1. Kennedy PG. 2013. Clinical features, diagnosis, treatment human
    regard selectivity, comparison T. brucei ThrRS             African trypanosomiasis (sleeping sickness). Lancet Neurol. 12:186 â€“194.
amino acid sequence human enzyme sequence shows                 http://dx.doi.org/10.1016/S1474-4422(12)70296-X. enzymes highly conserved  Fig. S1 supple-           2. Stuart K, Brun R, Croft S, Fairlamb  Gurtler  McKerrow J, Reed
                                                                              S, Tarleton R. 2008. Kinetoplastids: related protozoan pathogens, differ-
mental material). case E. coli enzyme,           ent diseases. J. Clin. Invest. 118:1301â€“1310. http://dx.doi.org/10.1172 recent study showed differences amino acid sequence             /JCI33945. second-shell residues exploited identify bisubstrate        3. Jacobs RT, Nare B, Phillips MA. 2011. State art African trypano-
analogs Thr adenine highly (â¬Ž300-fold) selective             drug discovery. Curr.  Med. Chem. 11:1255â€“1274. http://dx.doi bacterial enzyme (62). X-ray structure analysis showed           .org/10.2174/156802611795429167.
                                                                           4. Yun O, Priotto G, Tong J, Flevaud L, Chappuis F. 2010. NECT  replacement Leu361 Cys361 bacterial enzyme                  implementing new drug combination therapy Trypanosoma bru-
created enlarged binding pocket allowed inhibitors                 cei gambiense sleeping sickness. PLoS Negl. Trop. Dis. 4:e720. http://dx
adopt conformation bound E. coli enzyme                .doi.org/10.1371/journal.pntd.0000720.
different seen bound human                 5. Frearson JA, Wyatt PG, Gilbert IH, Fairlamb AH. 2007. Target assess-
enzyme. Examination putative Thr/ATP binding sites T.               ment antiparasitic drug discovery. Trends Parasitol. 23:589 â€“595. http:
                                                                              //dx.doi.org/10.1016/j.pt.2007.08.019.
brucei ThrRS shows T. brucei enzyme, like hu-           6. Brun R, Don R, Jacobs RT, Wang MZ, Barrett MP. 2011. Development
man enzyme, Leu residue position 361 (TbThrRS Leu                    novel drugs human African trypanosomiasis. Future Microbiol.
409), amino acid differences second-shell residues               6:677â€“ 691. http://dx.doi.org/10.2217/fmb.11.44.
present exploited identification selective        7. AgÃ¼ero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell
inhibitors  Fig. S1). borrelidin binding site, adja-         RK, Carmona S, Carruthers IM, Chan AW, Chen F, Crowther GJ,
                                                                              Doyle MA, Hertz-Fowler C, Hopkins AL, McAllister G, Nwaka S,
cent substrate binding site, explored bacterial aaRSs           Overington JP, Pain  Paolini GV, Pieper U, Ralph SA, Riechers  site-directed mutagenesis, identifying key residues           Roos DS, Sali  Shanmugam D, Suzuki T, Van Voorhis WC, Verlinde
conserved enzymes inhibited compound (53).                 CL. 2008. Genomic-scale prioritization drug targets: TDR Targets residues conserved T. brucei human                  database. Nat. Rev. Drug Discov. 7:900 â€“907. http://dx.doi.org/10.1038
enzymes, suggesting hard selectively target            /nrd2684.
                                                                           8. MagariÃ±os MP, Carmona SJ, Crowther GJ, Ralph SA, Roos DS, Shan-
site.  structural data available fully map             mugam D, Van Voorhis WC, AgÃ¼ero F. 2012. TDR Targets: chemog-
borrelidin binding site, making difficult determine species-         enomics resource neglected diseases. Nucleic Acids Res. 40:D1118 â€“
selective binding possible site.                        D1127. http://dx.doi.org/10.1093/nar/gkr1053.
    summary, demonstrate seven aaRSs,               9. Hopkins AL, Groom CR. 2002. druggable genome. Nat. Rev. Drug
                                                                              Discov. 1:727â€“730. http://dx.doi.org/10.1038/nrd892. subunits, essential infectious mammalian
                                                                          10. Baquero F, Blazquez J. 1997. Evolution antibiotic resistance. Trends Ecol. Evol.
form T. brucei previously showed AlaRs, ProRS,                 12:482â€“487. http://dx.doi.org/10.1016/S0169-5347(97)01223-8.
LeuRS, LysRS, IleRS essential mammalian            11. Gadakh B, Van Aerschot  2012. Aminoacyl-tRNA synthetase inhibitors
fective stage parasite (21, 30). addition genetic            antimicrobial agents: patent review 2006 till present. Expert
validation 13 aaRS genes, shown additional            Opin. Ther. Pat. 22:1453â€“1465. http://dx.doi.org/10.1517/13543776.2012
                                                                              .732571.
5 essential relevant mammalian stage life cycle.     12. Vondenhoff GH, Van Aerschot  2011. Aminoacyl-tRNA synthetase mRNA knockdown 60  70  sufficient cell                inhibitors potential antibiotics. Eur. J. Med. Chem. 46:5227â€“5236. http:
growth arrest  cases, cell death suggests aaRS         //dx.doi.org/10.1016/j.ejmech.2011.08.049.
inhibitor effective enzyme activity              13. Niemann M, Schneider  Cristodero M. 2011. Mitochondrial transla-
mained treated parasites. addition, enzymes              tion trypanosomatids: novel target chemotherapy? Trends Parasi-
                                                                              tol. 27:429 â€“ 433. http://dx.doi.org/10.1016/j.pt.2011.03.011.
alyzed study (ValRS, PheRS, ArgRS, ThrRS)             14. Wilson DN. 2009. bacterial translation inhibitors. Crit. Rev. Biochem. genetic validation data high  e., â¬Ž0.6) drug-              Mol. Biol. 44:393â€“433. http://dx.doi.org/10.3109/10409230903307311.
gability scores (Table 1) essential likely bind       15. Perona JJ, Hadd  2012. Structural diversity protein engineering small drug-like molecules good potency, making excel-               aminoacyl-tRNA synthetases. Biochemistry 51:8705â€“ 8729. http://dx
lent candidates future drug discovery efforts. Finally,           .doi.org/10.1021/bi301180x.
                                                                          16. Delarue M. 1995. Partition aminoacyl-tRNA synthetases differ-
provide preliminary chemical validation ThrRS showing                   ent structural classes dating early metabolism: implications borrelidin inhibitor T. brucei ThrRS T.             origin genetic code nature protein sequences. J. Mol. Evol.
brucei cell growth. aaRSs T. brucei chem-             41:703â€“711.
ically validated (Table 1);  development recombinant          17. Nagel GM, Doolittle RF. 1991. Evolution relatedness amino-
expression systems enzyme assays ThrRS                  acyl-tRNA synthetase families. Proc. Natl. Acad. Sci. U. S.  88:8121â€“
                                                                              8125. http://dx.doi.org/10.1073/pnas.88.18.8121.
aaRSs readies future drug discovery efforts, including           18. Oâ€™Donoghue P, Luthey-Schulten  2003. evolution structure
high-throughput screening novel inhibitors.                               aminoacyl-tRNA synthetases. Microbiol. Mol. Biol. Rev. 67:550 â€“573.
                                                                              http://dx.doi.org/10.1128/MMBR.67.4.550-573.2003.
ACKNOWLEDGMENTS                                                           19. Hoepfner D, McNamara CW, Lim CS, Studer C, Riedl R, Aust T,
                                                                              McCormack SL, Plouffe DM, Meister S, Schuierer S, Plikat U, Hart- work supported National Institutes Health grants (R01          mann N, Staedtler F, Cotesta S, Schmitt EK, Petersen F, Supek F,
AI078962)  K.S. M P.) Welch Foundation grant 1257           Glynne RJ, Tallarico JA, Porter JA, Fishman MC, Bodenreider C,
M P.). M P. holds Beatrice Miguel Elias Distinguished Chair       Diagana TT, Movva NR, Winzeler EA. 2012. Selective specific inhi- Biomedical Science Carolyn R. Bacon Professorship Medical       bition Plasmodium falciparum lysyl-tRNA synthetase fungal



514   ec.asm.org                                                                                                                                 Eukaryotic Cell
                                                                                                                                   T. brucei Aminoacyl tRNA Synthetases



      secondary metabolite cladosporin. Cell Host Microbe 11:654 â€“ 663. http:              prokaryotic homologs. J. Mol. Biol. 397:481â€“ 494. http://dx.doi.org/10
      //dx.doi.org/10.1016/j.chom.2012.04.015.                                             .1016/j.jmb.2010.01.051.
20.   Gowri VS, Ghosh  Sharma  Madhubala R. 2012. Unusual domain architec-       37.   Merritt EA, Arakaki TL, Gillespie R, Napuli AJ, Kim JE, Buckner FS,
      ture aminoacyl tRNA synthetases paralogs Leishmania major.         Van Voorhis WC, Verlinde CL, Fan E, Zucker F, Hol  2011. Crystal
      BMC Genomics 13:621. http://dx.doi.org/10.1186/1471-2164-13-621.                     structures protozoan homologs tryptophanyl-tRNA synthe-
21.   Cestari  Kalidas S, Monnerat S, Anupama  Phillips MA, Stuart K.                  tase. Mol. Biochem. Parasitol. 177:20 â€“28. http://dx.doi.org/10.1016/j
      2013. multiple aminoacyl-tRNA synthetase complex enhances                     .molbiopara.2011.01.003.
      tRNA-aminoacylation African trypanosomes. Mol. Cell. Biol. 33:4872â€“         38.   Willert EK, Phillips MA. 2008. Regulated expression essential allo-
      4888. http://dx.doi.org/10.1128/MCB.00711-13.                                        steric activator polyamine biosynthesis African trypanosomes. PLoS
22.   Alfonzo JD, Soll D. 2009. Mitochondrial tRNA importâ€ challenge                 Pathog. 4:e1000183. http://dx.doi.org/10.1371/journal.ppat.1000183.
      understand just begun. Biol. Chem. 390:717â€“722. http://dx.doi.org/10       39.   Kalidas S, Li Q, Phillips MA. 2011. Gateway((R)) compatible vector gene
      .1515/BC.2009.101.                                                                   silencing bloodstream form Trypanosoma brucei. Mol. Biochem. Parasitol.
23.   Tschopp F, Charriere F, Schneider  2011. vivo study Trypano-                 178:51â€“55. http://dx.doi.org/10.1016/j.molbiopara.2011.03.002.
      soma brucei links mitochondrial transfer RNA import mitochondrial           40.   Brun R, Schonenberger M. 1979. Cultivation vitro cloning       protein import. EMBO Rep. 12:825â€“ 832. http://dx.doi.org/10.1038                     procyclic culture forms Trypanosoma brucei semi-defined 
      /embor.2011.111.                                                                     dium. Acta Trop. 36:289 â€“292.
24.   EspaÃ±ol Y, Thut D, Schneider  Ribas Pouplana L. 2009. mech-             41.   Redmond S, Vadivelu J, Field MC. 2003. RNAit: automated web-based tool
      anism functional segregation mitochondrial cytosolic genetic              fortheselectionofRNAitargetsinTrypanosomabrucei.Mol.Biochem.Parasitol.
      codes. Proc. Natl. Acad. Sci. U. S.  106:19420 â€“19425. http://dx.doi.org           128:115â€“118. http://dx.doi.org/10.1016/S0166-6851(03)00045-8.
      /10.1073/pnas.0909937106.                                                      42.   Inoue M, Nakamura Y, Yasuda K, Yasaka N, Hara T, Schnaufer 
25.   CharriÃ F, Oâ€™Donoghue P, HelgadÃ³ttir S, MarÃ©chal-Drouard L, Cris-                  Stuart K, Fukuma T. 2005. 14-3-3 proteins Trypanosoma brucei
      todero M, Horn EK, SÃ¶ll D, Schneider 2009. Dual targeting                     function motility, cytokinesis, cell cycle. J. Biol. Chem. 280:14085â€“
      tRNAAsp requires different aspartyl-tRNA synthetases Trypano-                 14096. http://dx.doi.org/10.1074/jbc.M412336200.
      soma brucei. J. Biol. Chem. 284:16210 â€“16217. http://dx.doi.org/10.1074        43.   Wirtz E, Leal S, Ochatt C, Cross G. 1999. tightly regulated inducible
      /jbc.M109.005348.                                                                    expression conditional gene knock-outs dominant-
26.   CharriÃ F, HelgadÃ³ttir S, Horn EK, SÃ¶ll D, Schneider  2006. Dual                 negative genetics T. brucei. Mol. Biochem. Parasitol. 99:89 â€“101. http:
      targeting single tRNA(Trp) requires different tryptophanyl-tRNA             //dx.doi.org/10.1016/S0166-6851(99)00002-X.
      synthetases Trypanosoma brucei. Proc. Natl. Acad. Sci. U. S.  103:        44.   Schnaufer  Panigrahi AK, Panicucci B, Igo RP, Jr, Wirtz E, Salavati R,
      6847â€“ 6852. http://dx.doi.org/10.1073/pnas.0602362103.                               Stuart K. 2001. RNA ligase essential RNA editing survival 27.   Cristodero M, Seebeck T, Schneider  2010. Mitochondrial translation                bloodstream form Trypanosoma brucei. Science 291:2159 â€“2162.
      essential bloodstream forms Trypanosoma brucei. Mol. Microbiol.             http://dx.doi.org/10.1126/science.1058655.
      78:757â€“769. http://dx.doi.org/10.1111/j.1365-2958.2010.07368.x.                45.   BrenndÃ¶rfer M, Boshart M. 2010. Selection reference genes mRNA
28.   Rinehart J, Horn EK, Wei D, Soll D, Schneider  2004. Non-canonical
                                                                                           quantification Trypanosoma brucei. Mol. Biochem. Parasitol. 172:52â€“
      eukaryotic glutaminyl- glutamyl-tRNA synthetases form mitochon-
                                                                                           55. http://dx.doi.org/10.1016/j.molbiopara.2010.03.007.
      drial aminoacyl-tRNA Trypanosoma brucei. J. Biol. Chem. 279:1161â€“
                                                                                     46.   Winer J, Jung CK, Shackel  Williams PM. 1999. Development validation
      1166. http://dx.doi.org/10.1074/jbc.M310100200.
                                                                                           real-time quantitative reverse transcriptase-polymerase chain reaction 29.   Rettig J, Wang Y, Schneider  Ochsenreiter T. 2012. Dual targeting                                                                                            monitoring gene expression cardiac myocytes vitro. Anal. Biochem. 270:41â€“
      isoleucyl-tRNA synthetase Trypanosoma brucei mediated                                                                                            49. http://dx.doi.org/10.1006/abio.1999.4085.
      alternative trans-splicing. Nucleic Acids Res. 40:1299 â€“1306. http://dx.doi
                                                                                     47.   Tu X, Wang CC. 2004. involvement cdc2-related kinases
      .org/10.1093/nar/gkr794.
                                                                                           (CRKs) Trypanosoma brucei cell cycle regulation distinctive
30.   Cestari  Stuart K. 2013. Inhibition isoleucyl-tRNA synthetase                                                                                            stage-specific phenotypes caused CRK3 depletion. J. Biol. Chem. 279:
      potential treatment human African trypanosomiasis. J. Biol. Chem.
      288:14256 â€“14263. http://dx.doi.org/10.1074/jbc.M112.447441.                         20519 â€“20528. http://dx.doi.org/10.1074/jbc.M312862200.
31.   Zhao Y, Wang Q, Meng Q, Ding D, Yang H, Gao G, Li D, Zhu W, Zhou               48.   Tu X, Wang CC. 2005. Coupling posterior cytoskeletal morphogenesis
      H. 2012. Identification Trypanosoma brucei leucyl-tRNA synthetase                 G1/S transition Trypanosoma brucei cell cycle. Mol. Biol. Cell
      inhibitors pharmacophore- docking-based virtual screening                 16:97â€“105. http://dx.doi.org/10.1091/mbc.E04-05-0368.
      synthesis. Bioorg. Med. Chem. 20:1240 â€“1250. http://dx.doi.org/10.1016/j       49.   Carnes J, Schnaufer  McDermott SM, Domingo G, Proff R, Steinberg
      .bmc.2011.12.035.                                                                    AG, Kurtz  Stuart K. 2012. Mutational analysis Trypanosoma brucei
32.   Ding D, Meng Q, Gao G, Zhao Y, Wang Q, Nare B, Jacobs R, Rock F,                     editosome proteins KREPB4 KREPB5 reveals domains critical       Alley MR, Plattner JJ, Chen G, Li D, Zhou H. 2011. Design, synthesis,                function. RNA 18:1897â€“1909. http://dx.doi.org/10.1261/rna.035048.112.
      structure-activity relationship Trypanosoma brucei leucyl-tRNA          50.   Cestari  Stuart K. 2013. spectrophotometric assay quantitative
      synthetase inhibitors antitrypanosomal agents. J. Med. Chem. 54:1276 â€“            measurement aminoacyl-tRNA synthetase activity. J. Biomol. Screen.
      1287. http://dx.doi.org/10.1021/jm101225g.                                           18:490 â€“ 497. http://dx.doi.org/10.1177/1087057112465980.
33.   Shibata S, Gillespie JR, Kelley  Napuli AJ, Zhang  Kovzun KV,             51.   Panigrahi AK, Ogata Y, Zikova  Anupama  Dalley RA, Acestor N,
      Pefley RM, Lam J, Zucker FH, Van Voorhis WC, Merritt EA, Hol                      Myler PJ, Stuart KD. 2009. comprehensive analysis Trypanosoma
      Verlinde CL, Fan E, Buckner FS. 2011. Selective inhibitors methionyl-             brucei mitochondrial proteome. Proteomics 9:434 â€“ 450. http://dx.doi.org
      tRNA synthetase potent activity Trypanosoma brucei infec-               /10.1002/pmic.200800477.
      tion mice. Antimicrob. Agents Chemother. 55:1982â€“1989. http://dx.doi        52.   Ling J, Peterson KM, Simonovic  Cho C, Soll D, Simonovic M. 2012.
      .org/10.1128/AAC.01796-10.                                                           Yeast mitochondrial threonyl-tRNA synthetase recognizes tRNA isoac-
34.   Koh CY, Kim JE, Shibata S, Ranade RM, Yu M, Liu J, Gillespie JR,                     ceptors distinct mechanisms promotes CUN codon reassignment.
      Buckner FS, Verlinde CL, Fan E, Hol  2012. Distinct states                     Proc. Natl. Acad. Sci. U. S.  109:3281â€“3286. http://dx.doi.org/10.1073
      methionyl-tRNA synthetase indicate inhibitor binding conformational               /pnas.1200109109.
      selection. Structure 20:1681â€“1691. http://dx.doi.org/10.1016/j.str.2012        53.   Ruan B, Bovee ML, Sacher M, Stathopoulos C, Poralla K, Francklyn CS,
      .07.011.                                                                             Soll D. 2005. unique hydrophobic cluster near active site contributes
35.   Shibata S, Gillespie JR, Ranade RM, Koh CY, Kim JE, Laydbak JU,                      differences borrelidin inhibition threonyl-tRNA synthetases.
      Zucker FH, Hol  Verlinde CL, Buckner FS, Fan E. 2012. Urea-based                  J. Biol. Chem. 280:571â€“577. http://dx.doi.org/10.1074/jbc.M411039200.
      inhibitors Trypanosoma brucei methionyl-tRNA synthetase: selectivity        54.   Jackson KE, Pham JS, Kwek M, Silva NS, Allen SM, Goodman CD,
      vivo characterization. J. Med. Chem. 55:6342â€“ 6351. http://dx.doi             McFadden GI, Pouplana LR, Ralph SA. 2012. Dual targeting       .org/10.1021/jm300303e.                                                              aminoacyl-tRNA synthetases apicoplast cytosol Plasmodium
36.   Merritt EA, Arakaki TL, Gillespie JR, Larson ET, Kelley  Mueller N,                falciparum. Int. J. Parasitol. 42:177â€“186. http://dx.doi.org/10.1016/j
      Napuli AJ, Kim J, Zhang L, Verlinde CL, Fan E, Zucker F, Buckner FS,                 .ijpara.2011.11.008.
      van Voorhis WC, Hol  2010. Crystal structures trypanosomal               55.   Gao YM, Wang XJ, Zhang J, Li M, Liu CX, J, Jiang L, Xiang WS.
      histidyl-tRNA synthetase illuminate differences eukaryotic               2012. Borrelidin, potent antifungal agent: insight antifungal


April 2014 Volume 13 Number 4                                                                                                                            ec.asm.org 515
Kalidas et al.



      mechanism Phytophthora sojae. J. Agric. Food Chem. 60:9874 â€“                        D, Bacher J, Groll AH, Walsh TJ. 2004. Efficacy PLD-118, novel
      9881. http://dx.doi.org/10.1021/jf302857x.                                                  inhibitor candida isoleucyl-tRNA synthetase, experimental
56.   Habibi D, Ogloff N, Jalili RB, Yost  Weng AP, Ghahary  Ong CJ.                          oropharyngeal esophageal candidiasis caused fluconazole-resistant
      2012. Borrelidin, small molecule nitrile-containing macrolide inhibitor                   C. albicans. Antimicrob. Agents Chemother. 48:3959 â€“3967. http://dx.doi
      threonyl-tRNA synthetase, potent inducer apoptosis acute                      .org/10.1128/AAC.48.10.3959-3967.2004.
      lymphoblastic leukemia. Invest. New Drugs 30:1361â€“1370. http://dx.doi                 68.   Houge-Frydrych CS, Gilpin ML, Skett PW, Tyler JW. 2000. SB-203207
      .org/10.1007/s10637-011-97